JP2024502615A5 - - Google Patents
Info
- Publication number
- JP2024502615A5 JP2024502615A5 JP2023541664A JP2023541664A JP2024502615A5 JP 2024502615 A5 JP2024502615 A5 JP 2024502615A5 JP 2023541664 A JP2023541664 A JP 2023541664A JP 2023541664 A JP2023541664 A JP 2023541664A JP 2024502615 A5 JP2024502615 A5 JP 2024502615A5
- Authority
- JP
- Japan
- Prior art keywords
- svv
- inhibitor
- derivative
- checkpoint inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135914P | 2021-01-11 | 2021-01-11 | |
| US63/135,914 | 2021-01-11 | ||
| PCT/US2022/011994 WO2022150769A1 (en) | 2021-01-11 | 2022-01-11 | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502615A JP2024502615A (ja) | 2024-01-22 |
| JP2024502615A5 true JP2024502615A5 (enExample) | 2025-01-21 |
Family
ID=82357000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541664A Pending JP2024502615A (ja) | 2021-01-11 | 2022-01-11 | チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240100107A1 (enExample) |
| EP (1) | EP4274593A4 (enExample) |
| JP (1) | JP2024502615A (enExample) |
| KR (1) | KR20230130689A (enExample) |
| CN (1) | CN116782941A (enExample) |
| AU (1) | AU2022205429A1 (enExample) |
| CA (1) | CA3207860A1 (enExample) |
| IL (1) | IL304170A (enExample) |
| WO (1) | WO2022150769A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096201A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| WO2021016194A1 (en) | 2019-07-19 | 2021-01-28 | Racaniello Vincent R | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| WO2024054989A1 (en) * | 2022-09-08 | 2024-03-14 | Seneca Therapeutics, Inc. | Cancer therapies with oncolytic virus and an immune checkpoint inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638318B2 (en) * | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| WO2017096201A1 (en) * | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| EP3419643A4 (en) * | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
| TW201825511A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
| KR20220006531A (ko) * | 2019-04-11 | 2022-01-17 | 세네카 세라퓨틱스, 인크. | 암 치료를 위해 세네카 밸리 바이러스 (svv)를 사용하는 조성물 및 방법 |
-
2022
- 2022-01-11 EP EP22737296.8A patent/EP4274593A4/en active Pending
- 2022-01-11 WO PCT/US2022/011994 patent/WO2022150769A1/en not_active Ceased
- 2022-01-11 US US18/271,619 patent/US20240100107A1/en active Pending
- 2022-01-11 CN CN202280009533.9A patent/CN116782941A/zh active Pending
- 2022-01-11 CA CA3207860A patent/CA3207860A1/en active Pending
- 2022-01-11 KR KR1020237026908A patent/KR20230130689A/ko active Pending
- 2022-01-11 JP JP2023541664A patent/JP2024502615A/ja active Pending
- 2022-01-11 AU AU2022205429A patent/AU2022205429A1/en active Pending
-
2023
- 2023-07-02 IL IL304170A patent/IL304170A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goss et al. | Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor | |
| Puccini et al. | Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies | |
| JP2018521135A5 (enExample) | ||
| JP2021513536A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| Reardon et al. | Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma | |
| Ke et al. | TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling | |
| JP2021520406A5 (enExample) | ||
| Fishman et al. | Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma | |
| Chen et al. | Brief report: ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage SCLC: results of a phase 1b clinical trial | |
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| Li et al. | Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling | |
| JP2024535053A5 (enExample) | ||
| Oldenhuis et al. | A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies | |
| JP7653907B2 (ja) | ｐ５３ＷＴ腫瘍の処置の方法 | |
| Saunders et al. | Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study | |
| Munasinghe et al. | Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR | |
| Hamberg et al. | Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies | |
| Ding et al. | Safety and efficacy of paclitaxel liposome for elderly patients with advanced non‐small cell lung cancer: A multi‐center prospective study | |
| Hensley et al. | A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer | |
| Ramanathan | Alternative dosing schedules for cetuximab: a role for biweekly administration? | |
| Moosmann et al. | Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer | |
| Richardson et al. | Abstract CT131: a phase I safety and tolerance study of FN-1501, a novel FLT3 inhibitor, in patients with advanced solid tumors and acute myeloid leukemia | |
| Yan et al. | Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma | |
| Bar et al. | Multitargeted inhibitors in lung cancer: new clinical data |